Martin Mackay

Type: Person
Name: Martin Mackay
First reported Aug 27 2014 - Updated Aug 28 2014 - 1 reports

Alexion Launches Eculizumab Trial In Kidney Transplant DGF

By Estel Grace MasangkayAlexion announced that it has started dosing in its clinical trial evaluating eculizumab for the prevention of delayed graft function (DGF). The trial involves adult patients who have undergone kidney transplantation and who are ... [Published Bioresearch Online - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 1 reports

Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris) for the prevention of delayed graft function ... [Published FinanzNachrichten.de - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

The Case for Orphan Drugs

Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D. Approximately one-third of all new medicines approved by the FDA in the past 5 years were developed for the treatment of ... [Published Drug Discovery and Development - Aug 22 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Network key to supply

Supply chain: The head of a new NSW grain port said the industry needs to leverage off existing infrastructure and improve rail and road capacity to reap benefits. Source: News Corp AustraliaTHERE are simple ways to ­improve the nation’s grain supply ... [Published Weekly Times Now - Aug 20 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

European Commission Grants Orphan Drug Designation to Soliris® eculizumab for the Treatment of Patients with Myasthenia Gravis MG

By a News Reporter-Staff News Editor at Biotech Week -- Alexion Pharmaceuticals (NASDAQ:ALXN) announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis ... [Published HispanicBusiness.com - Aug 13 2014]
First reported Aug 05 2014 - Updated Aug 06 2014 - 2 reports

European Commission Grants Orphan Drug Designation To Soliris (eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG)

CHESHIRE, CONN.--(BUSINESS WIRE)--Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, ... [Published Laboratory Network - Aug 06 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

EC Designates Orphan Status To Alexion’s Soliris For MG

By Estel Grace MasangkayAlexion Pharmaceuticals reported that the European Commission has designated its drug Soliris (eculizumab) orphan drug status for the treatment of rare disease Myasthenia Gravis (MG).Soliris is a first-in-class inhibitor of terminal ... [Published Bioresearch Online - Aug 04 2014]
First reported Aug 02 2014 - Updated Aug 02 2014 - 1 reports

Neverfail sold to Artisan Infrastructure

In an interview with The Register, ex-Neverfail MD Martin Mackay has confirmed rumours that Neverfail has been sold to Artisan Infrastructure. No details of the agreement are available.Mr. Mackay told The Register:"I am not at liberty to give details ... [Published Continuity Central - Aug 02 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 2 reports

Orphan status in Europe for Alexion’s Soliris in myasthenia gravis

The European Commission has granted orphan drug designation (ODD) to US drugmaker Alexion Pharmaceuticals’ (Nasdaq: ALXN) Soliris (eculizumab) for the treatment of patients with myasthenia gravis (MG), a rare, debilitating neurologic disorder caused by ... [Published Pharma Letter - Aug 01 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Texan firm buys disaster recovery bods Neverfail

HP ProLiant Gen8: Integrated lifecycle automationUK business continuity specialist Neverfail has been acquired by US-based Artisan Infrastructure in a quiet and unannounced deal.Ex-Neverfail MD Martin Mackay said: ”I am not at liberty to give details ... [Published The Register - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

GLASGOW 2014: Commonwealth Games diaries - 25 July

The Glasgow Chamber of Commerce's Warm Up Breakfast event this morning will look at 'Glasgow: a City for Creative Business'. Speakers Martin Mackay of Clyde Gateway, Rufus Logan of BRE Scotland, Scott Simpson of Radiate, an integrated marketing communications ... [Published Meetpie - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Alexion Pharmaceuticals' (ALXN) CEO Leonard Bell on Q2 2014 Results - Earnings Call Transcript

OperatorGood morning, and welcome to the Alexion Pharmaceuticals, Incorporated Second Quarter 2014 Results Conference Call. Today's call is being recorded.For opening remarks and introductions, I would like to turn the conference over to Mr. Irving Adler, ... [Published Seeking Alpha - Jul 24 2014]

Quotes

"delayed graft function is a serious and significant complication to successful kidney transplantation, which can be life-threatening due to the risk of losing the transplanted organ" said Martin Mackay, Ph D , executive vice president and global head of R&D at Alexion...
"patients with mg develop debilitating muscle weakness, impairing their ability to walk, speak clearly, swallow and, in some cases, to breathe normally, which could lead to a life-threatening myasthenic crisis" said Martin Mackay , Ph D , Executive Vice President, Global Head of R&D at Alexion...
"mdc1a is a disease that aligns very well with our passion to develop and deliver first-in-class drug candidates that have the potential to transform the lives of people suffering with devastating disorders that currently have no treatment options" said Martin Mackay, Ph D , executive vice president, head of Global Research & Development at Alexion...
...the risk of DGF, a benefit that may have positive implications for longer-term kidney function and clinical outcomes for patients," Mackay said. "in addition, a significant number of donor kidneys are reportedly never used and thus discarded each year due to the risk of poor outcomes associated with dgf, therefore reducing the risk of dgf may enable more patients to receive a kidney transplant." The company intends to start a single multinational DGF registration trial with Soliris later in 2014. Latest News

More Content

All (17) | News (17) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Alexion Launches Eculizumab Trial In Kidney Tra... [Published Bioresearch Online - Aug 27 2014]
Alexion Initiates Multinational Registration Tr... [Published FinanzNachrichten.de - Aug 25 2014]
The Case for Orphan Drugs [Published Drug Discovery and Development - Aug 22 2014]
Network key to supply [Published Weekly Times Now - Aug 20 2014]
European Commission Grants Orphan Drug Designat... [Published HispanicBusiness.com - Aug 13 2014]
European Commission Grants Orphan Drug Designat... [Published Laboratory Network - Aug 06 2014]
Alexion receives orphan drug designation for So... [Published Pharmaceutical Technology - Aug 05 2014]
EC Designates Orphan Status To Alexion’s Soliri... [Published Bioresearch Online - Aug 04 2014]
Neverfail sold to Artisan Infrastructure [Published Continuity Central - Aug 02 2014]
Orphan status in Europe for Alexion’s Soliris i... [Published Pharma Letter - Aug 01 2014]
European Commission Grants Orphan Drug Designat... [Published Benzinga.com - Aug 01 2014]
Texan firm buys disaster recovery bods Neverfail [Published The Register - Jul 29 2014]
GLASGOW 2014: Commonwealth Games diaries - 25 July [Published Meetpie - Jul 25 2014]
Alexion Pharmaceuticals' (ALXN) CEO Leonard Bel... [Published Seeking Alpha - Jul 24 2014]
Prothelia, University of Nevada sign agreements... [Published PharmaBiz - Feb 15 2014]
Prothelia and the University of Nevada, Reno En... [Published PR Newswire - Feb 13 2014]
US FDA grants Alexion' Soliris orphan drug stat... [Published Pharmaceutical Business Review - Jan 22 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.